Accelerated approvals examined

被引：0

|

作者：

Emma Dorey

机构：

来源：

Nature Biotechnology | 2011年 / 29卷 / 3期

关键词：

D O I：

10.1038/nbt0311-176b

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：176 / 176

相关论文

共 50 条

[1] ARE FDA ACCELERATED APPROVALS UNCONDITIONAL APPROVALS?
Macaulay, R.
Tsang, R.
[J]. VALUE IN HEALTH, 2018, 21 : S94 - S94
[2] Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
Lemery, Steven
Pazdur, Richard
[J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (04) : 217 - 218
[3] Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
Steven Lemery
Richard Pazdur
[J]. Nature Reviews Clinical Oncology, 2022, 19 : 217 - 218
[4] Accelerated approvals under the microscope
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (06) : 409 - 411
[5] "Dangling" Accelerated Approvals in Oncology
Beaver, Julia A.
Pazdur, Richard
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (18):
[6] Accelerated approvals under the microscope
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2021, 20 : 409 - 411
[7] Challenges in accelerated approvals for gene therapies
Escandon, Rafael
Lantos, John
[J]. MOLECULAR THERAPY, 2023, 31 (09) : 2572 - 2574
[8] Conflicting signals on US accelerated approvals
Fox, JL
[J]. NATURE BIOTECHNOLOGY, 2005, 23 (09) : 1027 - 1028
[9] Conflicting signals on US accelerated approvals
Jeffrey L Fox
[J]. Nature Biotechnology, 2005, 23 : 1027 - 1028
[10] Accelerated drug approvals in oncology: Pros and cons
Thakur, Sayanta
Lahiry, Sandeep
[J]. INDIAN JOURNAL OF CANCER, 2021, 58 (01) : 114 - 118

← 1 2 3 4 5 →